JP2021513077A5 - - Google Patents

Info

Publication number
JP2021513077A5
JP2021513077A5 JP2020542645A JP2020542645A JP2021513077A5 JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5 JP 2020542645 A JP2020542645 A JP 2020542645A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5
Authority
JP
Japan
Prior art keywords
dementia
subject
adm
level
adrenomedullin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/052982 external-priority patent/WO2019154900A1/en
Publication of JP2021513077A publication Critical patent/JP2021513077A/ja
Publication of JP2021513077A5 publication Critical patent/JP2021513077A5/ja
Priority to JP2023174585A priority Critical patent/JP2024001208A/ja
Pending legal-status Critical Current

Links

JP2020542645A 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Pending JP2021513077A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174585A JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155682.0 2018-02-08
EP18155682 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174585A Division JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Publications (2)

Publication Number Publication Date
JP2021513077A JP2021513077A (ja) 2021-05-20
JP2021513077A5 true JP2021513077A5 (enExample) 2022-08-04

Family

ID=61188647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542645A Pending JP2021513077A (ja) 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Country Status (12)

Country Link
US (2) US20210302440A1 (enExample)
EP (1) EP3749959A1 (enExample)
JP (2) JP2021513077A (enExample)
KR (1) KR102717599B1 (enExample)
CN (2) CN119770645A (enExample)
AU (1) AU2019219071A1 (enExample)
BR (1) BR112020014940A2 (enExample)
CA (1) CA3090736A1 (enExample)
IL (1) IL276564A (enExample)
MX (1) MX421834B (enExample)
SG (1) SG11202006686SA (enExample)
WO (1) WO2019154900A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
US20230097988A1 (en) 2020-02-26 2023-03-30 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
IL295924A (en) 2020-02-26 2022-10-01 Pam Theragnostics Gmbh Use of peptidylglycine alpha-amidization monooxygenase (pam) for medicinal purposes
AU2021238591A1 (en) 2020-03-16 2022-11-17 Adrenomed Ag Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
JP2026510789A (ja) 2023-03-17 2026-04-10 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US20090306227A1 (en) 2005-08-31 2009-12-10 Toshiyuki Ioka Tablet for removing tongue coating
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
WO2009095454A2 (de) * 2008-02-01 2009-08-06 Brahms Aktiengesellschaft Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
IL283215B2 (en) * 2011-11-16 2024-05-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
HRP20170427T1 (hr) 2011-11-16 2017-06-16 Sphingotec Gmbh Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
RU2019103403A (ru) * 2016-07-08 2020-08-10 Сфинготек Гмбх Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью

Similar Documents

Publication Publication Date Title
JP2021513077A5 (enExample)
JP2024001208A5 (enExample)
US12286480B2 (en) Modulators of ROR1-ROR2 binding
Andersson et al. Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma
Chanez et al. Corticosteroid reversibility in COPD is related to features of asthma.
Feehally et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy
Dropcho Antiamphiphysin antibodies with small‐cell lung carcinoma and paraneoplastic encephalomyelitis
JP6457463B2 (ja) 処置方法
JP2016536332A5 (enExample)
Yamaguchi et al. Enzyme‐linked immunosorbent assay of Pro‐gastrin‐releasing peptide for small cell lung cancer patients in comparison with neuron‐specific enolase measurement
JP2008535494A5 (enExample)
JP2017501977A (ja) 肺高血圧症を治療するための組成物および方法
JP2017509692A5 (enExample)
CN115976196B (zh) ErbB3作为肺动脉高压生物标志物和治疗靶点的应用
CN110320368A (zh) 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
JP2024533873A5 (enExample)
EP4592679A1 (en) Use of discoidin domain receptor 2 in diagnosis of neurodegenerative diseases, and related computer readable medium
JP3095784B2 (ja) 炎症プロセスの病因を決定するための診断方法
WO2016065877A1 (zh) Cd166作为肝癌诊断血清标志物的应用及其试剂盒
KR102592460B1 (ko) 폐동맥고혈압 동물모델 및 이를 이용한 폐동맥고혈압 예방 또는 치료용 물질의 스크리닝 방법
WO2021221668A1 (en) Anti-sars-cov-2 monoclonal antibody compositions
JP2022509018A5 (enExample)
Hojs-Fabjan et al. Polyneuropathy in hemodialysis patients: the most sensitive electrophysiological parameters and dialysis adequacy
WO2024090571A1 (ja) Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬
WO2024154832A1 (ja) 全身性強皮症の検出方法